Human BTLA & NFAT-Luciferase Reporter Recombinant Cell Line, Jurkat (CAT#: IOC-LX148)

Creative Biolabs has developed several immune checkpoint stable cell Lines expressing the most popular immune checkpoints to accelerate clients' immunotherapy discovery and clinical translation. Recombinant Jurkat T cell expressing firefly luciferase gene under the control of NFAT response elements with constitutive expression of human BTLA (B and T lymphocyte associated, B and T lymphocyte attenuator, BTLA1, CD272, GenBank Accession #NM_181780). Which can be used in binding assays and functional assay.

Stable cell lines for increased reliability and reproducibility;
Protein expression at the cell surface validated by FACS or WB;

• Screen for inhibitors of BTLA/HVEM interaction in cell-based co-inhibitory bioassay

• Characterize the biological activity of BTLA and its interactions with ligands

Human

Jurkat

BTLA & NFAT-Luciferase Reporter

BTLA is an immunoglobulin domain-containing glycoprotein expressed on T cells, resting B cells, macrophages, DCs and, to a lesser extent, NK cells. BTLA acts as an inhibitory receptor on T cells, as anti-BTLA treatment results in T cell proliferation, and BTLA knockout mice demonstrate hyper-responsive immune activation. Subsequently, herpesvirus entry mediator (HVEM), a tumor necrosis factor receptor, was identified as a natural ligand for BTLA in mice and humans. Expression of HVEM by antigen-presenting cells (APCs) was capable of inducing BTLA-dependent T cell inhibition.